Business
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatide CARMEL, Ind.,
About this update from Mbx Biosciences, Inc.
[{"type":"text","content":"Dr. Moraitis brings deep experience in endocrinology to his role leading clinical development for MBX’s lead product candidate, canvuparatide\nCARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development. “Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “Andreas’ deep expertise in endocrinology and proven track record of leading clinical development programs, from Investigational New Drug (IND) application to New Drug Application (NDA), make him an exceptional addition to our leadership team as we advance canvuparatide and our growing pipeline of obesity and rare disease product candidates.” “I have dedicated my career to developing new approaches for people living with complex endocrine conditions,” said Dr. Moraitis. “I am delighted to join MBX and look forward to working with this talented and experienced team to advance canvuparatide and help bring new potential treatments to patients whose needs are not adequately managed by existing treatments.” Dr. Moraitis is a board-certified endocrinologist with extensive experience leading clinical development programs for endocrine and metabolic indications. Prior to joining MBX, Dr. Moraitis spent over a decade at Corcept Therapeutics, where he oversaw endocrine clinical development. While at Corcept, he led the design and execution of clinical programs in rare endocrine diseases, supported the initial NDA filing of relacorilant for hypercortisolism, and collaborated closely with regulatory authorities throughout the clinical development process. Dr. Moraitis previously served as Clinical Assistant Professor in the Endocrine Oncology Program at the University of Michigan and as volunteer clinical faculty at the VA Medical Center in Orlando. He completed a fellowship in Adult and Reproductive Endocrinology at the National Institutes of Health and holds an M.D. from the National ...